Microscopic view of immune cells attacking liver cancer cells, symbolizing hope for new treatments.

Hope on the Horizon: New Immunotherapy Shows Promise in Liver Cancer Treatment

Rhea Morgan monogram
Rhea Morgan in Health & Wellness October 2026 • 4 min read.

"A Phase 3 trial explores the effectiveness of tislelizumab versus sorafenib for advanced hepatocellular carcinoma, offering a beacon of hope for patients."


Liver cancer, specifically hepatocellular carcinoma (HCC), represents a significant global health challenge. Unresectable HCC, accounting for approximately 70% of diagnosed cases, often presents limited treatment options, underscoring the urgent need for innovative therapies.

Traditional treatments like sorafenib have provided some benefit, but newer approaches, particularly immunotherapies, are showing promising results. Among these, tislelizumab, a humanized anti-PD-1 antibody, is under investigation for its potential to revolutionize first-line treatment for advanced HCC.

A Phase 3 clinical trial is underway to assess the efficacy and safety of tislelizumab compared to sorafenib in patients with advanced HCC. This article delves into the details of the trial, its design, and what the initial findings could mean for patients and the future of liver cancer treatment.

AI Search Multiple angles on this topic

Immunotherapy’s Rising Role

A bibliometric study examined liver cancer research from 2020 to 2024 and identified immunotherapy as a key breakthrough for advanced cases. The study describes the COVID-19 pandemic as a force that transformed the field and shifted research priorities. A separate report says combination therapies are achieving response rates above 30%, although that figure comes from the report’s clinical-data summary.

The Promise of Tislelizumab: How Does it Work?

Microscopic view of immune cells attacking liver cancer cells, symbolizing hope for new treatments.

Tislelizumab, known as BGB-A317, is engineered to target the programmed cell death receptor-1 (PD-1), a key protein that regulates the immune system's response to cancer cells. By blocking PD-1, tislelizumab helps to unleash the immune system's ability to recognize and destroy cancer cells. What sets tislelizumab apart is its unique design that minimizes binding to macrophages, potentially reducing T-cell clearance and enhancing its effectiveness.

A previous Phase 1A/1B study (NCT02407990) laid the groundwork for further investigation, demonstrating that tislelizumab was generally well-tolerated and exhibited anti-tumor activity in patients with advanced solid tumors, including HCC. These encouraging results paved the way for the current Phase 3 trial, designed to rigorously evaluate its efficacy against the current standard of care, sorafenib.

  • Mechanism of Action: Tislelizumab targets PD-1, boosting the immune system's ability to fight liver cancer.
  • Phase 1 Success: Early trials showed promising results in terms of tolerability and anti-tumor activity.
  • Optimized Design: Engineered to minimize macrophage binding, potentially enhancing its effectiveness.
AI Search Multiple angles on this topic

Expanding Treatment Strategies

Recent reviews focus on combination immunotherapy and summarize clinical data from major immunotherapy trials. One review also examines using immunotherapy before liver transplantation in selected high-risk patients. Proposed strategies include combining immunotherapy with other treatments, using targeted therapies to alter the immune microenvironment, and developing agents that counteract inhibitory mechanisms in the liver.

Resistance and Limited Response

Reviews note that liver cancer remains difficult to treat and that current therapies often fail to produce long-term remission. Immunotherapy resistance may arise when an antitumor immune response cannot be initiated or when tumor-induced immunosuppression cannot be overcome. Although immunotherapy can produce complete and lasting tumor regression, only a subset of patients respond, and some patients relapse after an initial response.

Checkpoint Inhibitors Versus Sorafenib

In the phase 3 CheckMate 459 study, median overall survival was numerically longer with nivolumab, a PD-1 inhibitor, than with sorafenib in advanced hepatocellular carcinoma. The ORIENT-32 trial supported approval in China of sintilimab, another PD-1 inhibitor, combined with IBI305, a bevacizumab biosimilar, as first-line therapy. In the phase 3 HIMALAYA trial, durvalumab showed overall-survival noninferiority as monotherapy and superiority when combined with tremelimumab compared with sorafenib.

The ongoing Phase 3 study (NCT03412773) is a global, randomized, multicenter trial aimed at evaluating the efficacy and safety of tislelizumab compared to sorafenib as a first-line treatment for unresectable HCC. The trial design involves enrolling adult patients (≥18 years) with histologically confirmed HCC, an ECOG score ≤1, Child-Pugh A classification, BCLC Stage C disease, or BCLC Stage B disease that has relapsed after loco-regional therapy, and who have not received prior systemic therapy.

What's Next? The Future of Liver Cancer Treatment

As the Phase 3 trial progresses, the medical community eagerly awaits the results, which could potentially reshape the treatment landscape for advanced HCC. If tislelizumab proves superior or even non-inferior to sorafenib, it could offer a new, more effective option for patients. The study's exploratory endpoints, including the assessment of predictive biomarkers and the characterization of the tislelizumab pharmacokinetic profile, may also provide valuable insights into patient selection and treatment optimization. These advancements bring renewed hope for improving outcomes and enhancing the quality of life for individuals affected by this challenging disease.

AI Search Multiple angles on this topic

Keeping Pace With a Changing Field

Recent evidence supporting an immunotherapy survival benefit is contributing to a rapidly evolving treatment landscape in hepatocellular carcinoma. Clinicians need to stay current on patient selection and response rates compared with other systemic treatments. Management of immune-mediated adverse events is another important part of applying these therapies.

Reading the survival and response measures

The survival comparison supports noninferiority, not proof that tislelizumab extends life more than sorafenib: the trial’s primary endpoint was to rule out survival that was unacceptably worse by its prespecified margin. The median figures alone do not establish superiority.[1]

Responses lasted longer on average and began sooner with tislelizumab, while median progression-free survival was shorter than with sorafenib. Taken together, these measures describe different aspects of tumor response and disease progression, rather than a uniformly better result on every measure.[1]

How tislelizumab compares with earlier treatment evidence

Against that established comparator, the tislelizumab trial met its stated survival noninferiority endpoint, while its progression-free survival median favored sorafenib. The response-duration and response-timing results favored tislelizumab, so the comparison depends on which outcome is considered.[1]

The reported survival pattern was consistent across predefined subgroups, though the apparent benefit was less pronounced in the Asia subgroup excluding Japan than in the Japan and rest-of-world subgroups. Differences in disease extent, extrahepatic spread, and performance status were offered as possible influences, so subgroup variation is not a simple regional effect.[1]

What the comparisons leave unresolved

  • What accounts for the less pronounced survival benefit in the Asia subgroup excluding Japan, and how much do the noted differences in disease extent, extrahepatic spread, and performance status explain it?[1]
  • How do the observed differences in treatment-related adverse events relate to the distinct adverse-effect profiles, including hypertension, proteinuria, diarrhea, fatigue, and hypothyroidism?[1] [2]

Sources

  1. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (pmc.ncbi.nlm.nih.gov)
  2. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is tislelizumab and how does it work to fight liver cancer?

Tislelizumab is an immunotherapy, specifically a humanized anti-PD-1 antibody. Its primary function is to block the programmed cell death receptor-1 (PD-1). PD-1 is a protein that regulates the immune system's response to cancer cells. By blocking PD-1, tislelizumab enhances the immune system's capability to identify and destroy cancer cells. Its unique design minimizes binding to macrophages, potentially reducing T-cell clearance and boosting its effectiveness.

2

Why is there so much focus on this Phase 3 clinical trial involving tislelizumab?

The Phase 3 clinical trial is significant because it compares tislelizumab to sorafenib, a current standard treatment, for advanced hepatocellular carcinoma (HCC). The trial assesses the efficacy and safety of tislelizumab as a first-line treatment for unresectable HCC. If tislelizumab proves superior, it could provide a new, more effective option for patients with limited treatment options. It could reshape the treatment landscape for advanced HCC.

3

What is sorafenib, and why is it being compared to tislelizumab in the study?

Sorafenib is a traditional treatment option for advanced hepatocellular carcinoma (HCC). However, its effectiveness is limited, creating the need for innovative therapies. In the context of the Phase 3 trial, sorafenib serves as the comparator against which tislelizumab's efficacy is measured. The trial aims to determine if tislelizumab offers a superior or non-inferior alternative to sorafenib, potentially improving outcomes for patients with advanced HCC.

4

Why was the Phase 1 study of tislelizumab so important?

The Phase 1 study was important because it demonstrated that tislelizumab was generally well-tolerated and exhibited anti-tumor activity in patients with advanced solid tumors, including HCC. These encouraging results laid the groundwork for the Phase 3 trial, designed to rigorously evaluate its efficacy against the current standard of care, sorafenib. It helped prove the drug was safe enough to use on humans and that it had a positive effect on tumors.

5

What are the specific criteria for patients to be included in the Phase 3 trial?

The trial enrolls adult patients (≥18 years) with histologically confirmed HCC, an ECOG score ≤1, Child-Pugh A classification, BCLC Stage C disease, or BCLC Stage B disease that has relapsed after loco-regional therapy, and who have not received prior systemic therapy. ECOG (Eastern Cooperative Oncology Group) score and Child-Pugh scores are used to measure the performance status (how the disease is affecting their daily living abilities) and liver function of the patient. BCLC (Barcelona Clinic Liver Cancer) staging system assesses the stage of the cancer. These criteria ensure that the trial focuses on patients with advanced HCC who have not received prior systemic treatment, allowing for a fair comparison between tislelizumab and sorafenib.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.